In most clinical risk groups, immune response to vaccination is maintained and high levels of VE are seen with both the Pfizer and AstraZeneca vaccines. Reduced antibody response and vaccine effectiveness were seen after one dose of vaccine among the immunosuppressed group, however, after a second dose there is only a small and non-significant reduction in vaccine effectiveness. These findings would support maximising coverage with two doses in immunosuppressed individuals
..however, after a second dose there is only a... - CLL Support
..however, after a second dose there is only a small and non-significant reduction in vaccine effectiveness
Hello Zaax, thank you for the interesting read. I sincerely hope the information is accurate.
I doubt it is accurate as it was only 9 people and who knows whether they were on active treatment, in remission or W&W sadly I dont think us on treatment have much cover even if we have had 2 jabs ..going by several peer reviewed bits i have read so far ..I think this is government propaganda
It would seem that, on one hand, they say there is a nonsignificant reduction in vaccine effectiveness within the immunosuppressed group but, on the other, the response may not be as good.
But….Within these clinical risk groups, there will be people with more severe forms of illness – particularly in the immunosuppressed group – who may not respond as well to the vaccines, and we recommend they seek advice from their specialists.
And….
If the planned booster programme goes ahead, the JCVI has recommended that immunosuppressed adults and their household contacts should also be among the first to be offered a third dose of vaccine in September.
There are so many problems with this government statement it's hard to know where to begin,. Vaccine protect is at best unpredictable in CLL. Other immune compromised groups, ie HIV+ on ARD do fine. Lumping us together is a terrible abuse of data.
This PHE study is highly suspect when it comes to immunosuppressed.
As I read the Birmingham study which was a few more than 9 individuals the VE isnt that good sadly
The Birmingham study has its own issues, but at least it's independent.
Tune in later for an update! healthunlocked.com/cllsuppo...
If you did tune in, you'll have heard Dr Helen Parry's sceptical assessment of those numbers from PHE.
I missed it but I did read their preliminary report on their study .and extrapolated from that ..Im just very please that at least someone is batting on our side since the government certainly are not sadly
She's a scientist, so her assessment can be considered neutral. The video should be out soon.
Just had a letter from her with results ...sadly it doesnt mention obinutumazab or venetoclax apart from there not being enough people on it to show any results
Results - aggregate not yours I take it?
The video is out
healthunlocked.com/cllsuppo...
Treatment with Obinutuzumab impairs Ab production for some while unfortunately. The Israeli study found no antibodies in any participants who'd been on a CD20 Ab less than 12 months before vaccination.